TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03726879

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Doxorubicin will be administered as per the schedule specified in the respective arm.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Doxorubicin
Description: Doxorubicin will be administered as per the schedule specified in the respective arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide will be administered as per the schedule specified in the respective arm.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cyclophosphamide
Description: Cyclophosphamide will be administered as per the schedule specified in the respective arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel will be administered as per the schedule specified in the respective arm.
Study: NCT03330158

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ASTS
Description: Implantation of a motorized spinal distraction rod
Study: NCT00248612

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venlafaxine
Description: Participants will be assigned to a 12-week treatment condition; all treatment conditions will begin with a 1-week placebo run-in, after which participants will begin a trial of venlafaxine. The treatments will conclude with a 2-week medication taper.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Venlafaxine
Description: Participants will be assigned to a 12-week treatment condition; all treatment conditions will begin with a 1-week placebo run-in, after which participants will begin a trial of venlafaxine. The treatments will conclude with a 2-week medication taper.
Study: NCT01607671

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Timolol maleate
Description: Timolol 0.5% 1 drop twice daily to the effected eye for 4 weeks.
Study: NCT04562493

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transforaminal Epidural injection
Description: Transforaminal injection will be performed under fluoroscopy guidance. The patient will be placed in the prone position and draped in the sterile manner. A 22-gauge, 3.5-inch spinal needle will be used. The selected patients will receive transforaminal epidural injection of the drug

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transforaminal Epidural injection
Description: Transforaminal injection will be performed under fluoroscopy guidance. The patient will be placed in the prone position and draped in the sterile manner. A 22-gauge, 3.5-inch spinal needle will be used. The selected patients will receive transforaminal epidural injection of the drug

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Transforaminal Epidural injection
Description: Transforaminal injection will be performed under fluoroscopy guidance. The patient will be placed in the prone position and draped in the sterile manner. A 22-gauge, 3.5-inch spinal needle will be used. The selected patients will receive transforaminal epidural injection of the drug
Study: NCT01012076

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Active Control vs Experimental Treatment
Description: The parent education program involves 12 in-home training sessions (90 minutes each), is administered by trained graduate and postdoctoral students in developmental psychology or a related field, and follows a standardized treatment manual (Siller, 2005). The active control involves three 90 minute in-home training sessions. These training sessions will be administered by trained graduate students or a postdoctoral student in a developmental psychology or related field. The active control will follow a standardized treatment manual (Kasari, 2008). This treatment manual was based upon the teacher training workshops created by the Center on the Social and Emotional Foundations for Early Learning.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Active Control vs Experimental Treatment
Description: The parent education program involves 12 in-home training sessions (90 minutes each), is administered by trained graduate and postdoctoral students in developmental psychology or a related field, and follows a standardized treatment manual (Siller, 2005). The active control involves three 90 minute in-home training sessions. These training sessions will be administered by trained graduate students or a postdoctoral student in a developmental psychology or related field. The active control will follow a standardized treatment manual (Kasari, 2008). This treatment manual was based upon the teacher training workshops created by the Center on the Social and Emotional Foundations for Early Learning.
Study: NCT02138435

Intervention type: OTHER
Intervention: MRI exercise test
Description: Measuring cardiac output with MRI during exercise on an ergometer bicycle.

Intervention type: OTHER
Intervention: MRI exercise test
Description: Measuring cardiac output with MRI during exercise on an ergometer bicycle.

Intervention type: OTHER
Intervention: Gas-exchange exercise test
Description: Measuring cardiac output by gas-exchange, while during exercise on an ergometer bicycle.

Intervention type: OTHER
Intervention: Gas-exchange exercise test
Description: Measuring cardiac output by gas-exchange, while during exercise on an ergometer bicycle.
Study: NCT03698331

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valbenazine
Description: vesicular monoamine transporter 2 (VMAT2) inhibitor

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: non-active dosage form

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo oral capsule
Description: non-active dosage form
Study: NCT04460456

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SBT6050
Description: Escalating doses of SBT6050 in Part 1 and recommended dose in Part 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SBT6050
Description: Escalating doses of SBT6050 in Part 1 and recommended dose in Part 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SBT6050
Description: Escalating doses of SBT6050 in Part 1 and recommended dose in Part 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pembrolizumab
Description: 400 mg IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cemiplimab
Description: 350 mg IV
Study: NCT00678080

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin 500 mg orally daily increased as needed to maintain glycemic control until a maximum of 2500 daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin (NPH and Regular)
Description: Insulin will be administered based on maternal gestational age and maternal weight using NPH and Regular insulin. It will be administered subcutaneously 3 times a day
Study: NCT02386306

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GC021109

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GC021109

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GC021109

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00990938

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMO-2125
Description: IMO 2125 is a synthetic DNA-based agonist of Toll-like receptor 9, which is expressed in humans in plasmacytoid dendritic cells and B cells of the immune system.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Subcutaneous injection once per week for four weeks
Study: NCT03360747

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AKCEA-ANGPTL3-LRx
Description: AKCEA-ANGPTL3-LRx at dose 20 mg, administered via SC injection QW.
Study: NCT01690429

Intervention type: DEVICE
Group type: OTHER
Intervention: Somnocheck micro
Description: Study nights in sleep lab with standard polysomnography plus Somnocheck micro. The Somnocheck micro is a device with pulse oxymetry and nasal cannula, which can be worn like a wristwatch. It records information about sleep disordered breathing, oxygen saturation, and pulse wave.
Study: NCT02484690

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Faricimab
Description: Faricimab will be administered as per the regimen specified in the individual arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Faricimab
Description: Faricimab will be administered as per the regimen specified in the individual arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Faricimab
Description: Faricimab will be administered as per the regimen specified in the individual arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Faricimab
Description: Faricimab will be administered as per the regimen specified in the individual arm.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ranibizumab
Description: Ranibizumab will be administered as per the regimen specified in the individual arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranibizumab
Description: Ranibizumab will be administered as per the regimen specified in the individual arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sham Procedure
Description: The sham is a procedure that mimics an intravitreal injection, but involves the blunt end of an empty syringe (without a needle) being pressed against the anesthetized eye. It will be administered to participants in treatment arm D at applicable visits to maintain masking.
Study: NCT02127723

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hyaluronic acid injection (Macrolane VRF30)
Description: Injection of Macrolane subcutaneously in the buttocks area to reduce cellulite
Study: NCT02976051

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: HART-CN
Description: HART-CN: Hyperfractionated accelerated radiotherapy with weekly concommitant cis-platin and daily nimorazole
Study: NCT02054754

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexanabinol Dose Level 1
Description: Oral formulation of dexanabinol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexanabinol Dose Level 2
Description: Oral formulation of dexanabinol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexanabinol Dose Level 3
Description: Oral formulation of dexanabinol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexanabinol Dose Level 4
Description: Oral formulation of dexanabinol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexanabinol Dose Level 5
Description: Oral formulation of dexanabinol

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT04807062

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: surgery
Description: tunnel bone tamps method (TBTM) was used to reduce the depressed articular fragments and then structural bicortical autologous ICBG was used to fill the valley tunnel.
Study: NCT02973269

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: daxibotulinumtoxin type A
Description: Intramuscular injection

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intramuscular injection
Study: NCT02190318

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Losartan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Losartan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: spirolactone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: spirolactone
Study: NCT03783091

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxocobalamin
Description: Single IV administration of Vitamin B12

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single IV administration of saline
Study: NCT00248612

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CBT
Description: CBT is Cognitive Behavioral Therapy. Participants will be assigned to a 12-week treatment condition; all treatment conditions will begin with a 1-week placebo run-in, after which participants will begin a trial. The treatments will conclude with a 2-week medication/placebo taper.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBT
Description: CBT is Cognitive Behavioral Therapy. Participants will be assigned to a 12-week treatment condition; all treatment conditions will begin with a 1-week placebo run-in, after which participants will begin a trial. The treatments will conclude with a 2-week medication/placebo taper.
Study: NCT03726879

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Paclitaxel
Description: Paclitaxel will be administered as per the schedule specified in the respective arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Trastuzumab will be administered as per the schedule specified in the respective arm.
Study: NCT02190318

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: blank control
Study: NCT04320576

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bulk-fill
Description: Bulk-fill resin composite (bulk technique)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Nano-fill
Description: Nano-fill resin composite (layering technique)
Study: NCT03212820

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Drilling at low speed

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Drilling at conventional or high speed
Study: NCT00248612

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Progressive muscle relaxation therapy (PMR)
Description: For patients with comorbid alcohol-use and anxiety disorders, CBT and pharmacotherapy will be contrasted with relaxation training and placebo medication; all treatment conditions will begin with a 1-week placebo run-in, after which participants will begin a trial of venlafaxine or placebo.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Progressive muscle relaxation therapy (PMR)
Description: For patients with comorbid alcohol-use and anxiety disorders, CBT and pharmacotherapy will be contrasted with relaxation training and placebo medication; all treatment conditions will begin with a 1-week placebo run-in, after which participants will begin a trial of venlafaxine or placebo.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo medication
Description: For patients with comorbid alcohol-use and anxiety disorders, CBT and pharmacotherapy will be contrasted with relaxation training and placebo medication; all treatment conditions will begin with a 1-week placebo run-in, after which participants will begin a trial of venlafaxine or placebo.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo medication
Description: For patients with comorbid alcohol-use and anxiety disorders, CBT and pharmacotherapy will be contrasted with relaxation training and placebo medication; all treatment conditions will begin with a 1-week placebo run-in, after which participants will begin a trial of venlafaxine or placebo.
Study: NCT03079375

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: basic intervention
Description: medication review

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: extended intervention
Description: medication review, medication interview before discharge and follow-up
Study: NCT00991276

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pregabalin
Description: capsules; 300 mg once-per-day; 4 weeks of treatment

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: capsules; 0 mg once-per-day; 4 weeks of treatment

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pramipexole
Description: capsules; 0.5 mg once-per-day; 4 weeks of treatment
Study: NCT01214902

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Constraint induced movement therapy (CIMT)
Description: soft mitten worn on the non hemiplegic hand

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: play
Description: play which encourages the use of the hemiplegic hand
Study: NCT04660084

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Ultra-rapid molecular point-of-care testing
Description: Ultra-rapid molecular testing (UR-MT) comprises automated detection using the new BioFire® FilmArray® Pneumonia plus platform (Biomérieux). The total turn-around time is \<2 hrs.~The UR-MT is combined with standard of care, comprising:~Microbiological processing per current standard of care entails culture of respiratory tract samples according to national protocols to detect respiratory bacteria, identified using biochemical methods and/or matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF MS). Respiratory viruses are identified using real-time PCR (for metapneumovirus, rhinovirus, influenza A, influenza B, parainfluenza 1-3, RSV and SARS-CoV-2). The total turn-around time is up to 48 hrs.
Study: NCT03035240

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Financial Education
Description: Participants randomized to financial education will undergo a year long financial education. This involves 9 weeks of weekly classes followed by one on one coaching for a year.
Study: NCT01896492

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: NAC
Description: NAC 2gm plus cc 100mg from 3rd day of the cycle till day 8 with u/s follow up of the follicular growth.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NAC
Description: NAC 2gm plus cc 100mg from 3rd day of the cycle till day 8 with u/s follow up of the follicular growth.
Study: NCT00579631

Intervention type: BEHAVIORAL
Intervention: Questionnaire or Interview
Description: Complete a self-report survey once over the telephone or by mail. The questions are about your health beliefs and behaviors, your current health, and your mood. It should not take longer than 45 minutes to complete. About 15 of these people will participate in an additional, short audiotaped interview about sun protection.
Study: NCT03241186

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: 1mg/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: 3mg/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: 480mg
Study: NCT03485001

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: This group will not receive argon laser medical treatment; instead, they will be only exposed to the slit lamp light.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Argon Laser Treatment
Description: This group will receive argon laser medical treatment to the body and head of pterygium
Study: NCT04084990

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: S9 VPAP Adapt
Description: Auto-titrated positive airway pressure
Study: NCT02612129

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: arimoclomol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: arimoclomol
Study: NCT02129062

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Given orally 560 mg daily (dispensed as 4 x 140-mg capsules)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT01954901

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen therapy

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Hyperbaric room air
Study: NCT03450629

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brimonidine Tartrate Ophthalmic Suspension
Description: PDP-716

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Brimonidine Tartrate Ophthalmic Solution
Description: Three Times Brimonidine Tartrate Ophthalmic Solution
Study: NCT01109849

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: behavior therapy
Description: combination of individual and group parent training plus school consultation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Extended release (ER) methylphenidate product
Description: medication to be taken daily for duration of study unless assigned to weight promotion arm

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: monitoring
Description: monthly weight, height and BMI checks

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: drug holiday
Description: switch from seven day a week dosing to medication only on school days

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: caloric supplement
Description: continue current ADHD regimen and add one 8oz liquid caloric supplement at night
Study: NCT01720043

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Velcade
Description: Single dose of Velcade (1.0-1.3 mg/m2 dose)
Study: NCT02527850

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: B-cure laser

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: B-cure laser
Study: NCT03504449

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: neoadjuvant chemoradiotherapy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: neoadjuvant chemoradiotherapy
Study: NCT02157714

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRX002

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02392338

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Hybrid procedure
Description: Eletrophysiologic study via femoral vein approach to confirm pulmonary vein isolation lesion and box lesions in left atrium
Study: NCT02612129

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03252938

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMP321
Description: LAG-3Ig fusion protein, highly potent activator of antigen presenting cells

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMP321
Description: LAG-3Ig fusion protein, highly potent activator of antigen presenting cells

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMP321
Description: LAG-3Ig fusion protein, highly potent activator of antigen presenting cells

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMP321
Description: LAG-3Ig fusion protein, highly potent activator of antigen presenting cells

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMP321
Description: LAG-3Ig fusion protein, highly potent activator of antigen presenting cells

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: Avelumab i.v.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: Avelumab i.v.